What is William Blair’s Forecast for APLS Q3 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Equities researchers at William Blair issued their Q3 2024 earnings estimates for Apellis Pharmaceuticals in a research report issued to clients and investors on Wednesday, October 16th. William Blair analyst L. Hanbury-Brown forecasts that the company will earn ($0.26) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.37) per share. William Blair also issued estimates for Apellis Pharmaceuticals’ Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($1.25) EPS and FY2025 earnings at $0.34 EPS.

A number of other research firms have also recently commented on APLS. UBS Group reduced their price target on shares of Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating for the company in a report on Friday, August 9th. The Goldman Sachs Group raised their price objective on shares of Apellis Pharmaceuticals from $66.00 to $74.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Wells Fargo & Company dropped their price objective on shares of Apellis Pharmaceuticals from $47.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Tuesday, September 24th. Robert W. Baird dropped their price objective on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating on the stock in a research note on Monday, September 23rd. Finally, Wedbush raised their price objective on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Four investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $68.00.

Apellis Pharmaceuticals Trading Up 0.3 %

NASDAQ:APLS opened at $28.00 on Friday. The company has a current ratio of 5.08, a quick ratio of 4.18 and a debt-to-equity ratio of 1.73. The stock has a market capitalization of $3.40 billion, a price-to-earnings ratio of -8.09 and a beta of 0.87. The firm has a fifty day simple moving average of $34.16 and a two-hundred day simple moving average of $39.62. Apellis Pharmaceuticals has a 12 month low of $26.28 and a 12 month high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.03. The company had revenue of $199.70 million during the quarter, compared to analysts’ expectations of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. Apellis Pharmaceuticals’s revenue for the quarter was up 110.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.02) earnings per share.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several large investors have recently modified their holdings of the business. HighVista Strategies LLC grew its stake in Apellis Pharmaceuticals by 4.1% during the second quarter. HighVista Strategies LLC now owns 7,566 shares of the company’s stock valued at $290,000 after acquiring an additional 300 shares in the last quarter. Amalgamated Bank lifted its position in Apellis Pharmaceuticals by 5.4% during the second quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock valued at $268,000 after purchasing an additional 359 shares during the last quarter. Simplicity Wealth LLC lifted its position in Apellis Pharmaceuticals by 0.6% during the second quarter. Simplicity Wealth LLC now owns 78,746 shares of the company’s stock valued at $3,021,000 after purchasing an additional 499 shares during the last quarter. Future Financial Wealth Managment LLC bought a new stake in Apellis Pharmaceuticals during the first quarter valued at approximately $29,000. Finally, Oppenheimer Asset Management Inc. lifted its position in Apellis Pharmaceuticals by 8.3% during the first quarter. Oppenheimer Asset Management Inc. now owns 8,694 shares of the company’s stock valued at $511,000 after purchasing an additional 664 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Insider Buying and Selling

In other news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $36.23, for a total value of $1,340,510.00. Following the completion of the transaction, the director now owns 100,000 shares in the company, valued at $3,623,000. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.80% of the stock is currently owned by corporate insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).